financetom
Business
financetom
/
Business
/
What's Going On With NIO Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With NIO Stock Today?
Feb 14, 2025 5:23 AM

NIO Inc. ( NIO ) shares are trading higher in the premarket session on Friday.

The company announced a breakthrough in aluminum alloy technology, in which it has developed a self-hardening aluminum alloy for high-pressure die casting, already used in the body-in-white of its Nio ET9 and Onvo L60, reports CnEV Post.

This new alloy aims to improve performance and cost-efficiency in EV manufacturing and will be available to the entire industry.

This is the first self-hardening alloy for large structural castings developed by a Chinese automotive brand, challenging the dominance of C611 aluminum in China’s die casting market, per the report.

According to Benzinga Pro, NIO stock has lost over 29% in the past year. Investors can gain exposure to the stock via KraneShares Electric Vehicles and Future Mobility Index ETF .

Also Read: Upwork Gains On AI And Enterprise Growth, But Analysts See Macro Challenges Limiting Upside

In a recent internal meeting, NIO’s founder, chairman, and CEO, William Li, outlined strategic goals for the company, including doubling sales, achieving single-quarter profitability by Q4 2025, and enhancing its systematic capabilities. The meeting also celebrated NIO’s 10th anniversary.

Meanwhile, NIO’s performance during the Chinese New Year holiday also stands out. The company saw a surge in demand for its battery swap services, with 136,720 services recorded on February 3 alone.

This marked a peak in demand following a strong performance on January 25, with 119,848 services in a single day.

Price Action: NIO shares are trading higher by 1.88% to $4.35 premarket at last check Friday.

Read Next:

Tesla’s Vietnamese Rival VinFast’s Explosive Growth: 342% Surge In Q4 EV Deliveries Amid Ambitious 2025 Goals

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved